Medtronic (NYSE:MDT) said last week that it inadvertently omitted an undisclosed number of patient deaths from recent studies of its paclitaxel-coated balloons.
The company noted that the mistake ultimately does not affect the conclusion that there was no statistically significant difference in all-cause mortality between its In.Pact Admiral drug-coated balloon and plain balloon angioplasty at five years.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis appeared first on MassDevice.